Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects, belonging to the piperazine derivative family of drugs. It was manufactured by Stuart Pharms and initially approved by the FDA in 1957. Following this, it was touted to be effective as an appetite stimulant in children when administered in the syrup form, however, this indication has not been validated. In addition to the above conditions, buclizine has been studied in the treatment of migraine attacks and in the treatment of nausea and vomiting during pregnancy. It is grouped under the following drug class(es): Antiemetics. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Histabutizine and Aphilan-R base. Its PubChem CID is 6729.
Buclizine
| CAS No | 82-95-1 |
|---|---|
| Molecular Formula | C28H33ClN2 |
| Molecular Weight | 433.0 g/mol |
| Synonyms | 1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Buclizine is an antihistamine medication with both antiemetic and anticholinergic effects, belonging to the piperazine derivative family of drugs. It was manufactured by Stuart Pharms and initially approved by the FDA in 1957.
The listed CAS number is 82-95-1.
The listed molecular formula is C28H33ClN2.
The listed molecular weight is 433.0 g/mol.
1-[(4-tert-butylphenyl)methyl]-4-[(4-chlorophenyl)-phenylmethyl]piperazine.
The source lists Histabutizine and Aphilan-R base.